GOSS - Gossamer Bio, Inc.

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
19.00
-0.74 (-3.75%)
At close: 4:00PM EDT
Stock chart is not supported by your current browser
Previous Close19.74
Open19.74
Bid18.99 x 1000
Ask19.00 x 800
Day's Range18.96 - 20.00
52 Week Range15.59 - 25.06
Volume143,327
Avg. Volume175,955
Market Cap1.252B
Beta (3Y Monthly)N/A
PE Ratio (TTM)N/A
EPS (TTM)-10.86
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est30.00
Trade prices are not sourced from all markets
  • Seth Klarman's Favorite Biotech Positions
    GuruFocus.comlast month

    Seth Klarman's Favorite Biotech Positions

    Some ideas from Baupost's pharmaceutical portfolio

  • Seth Klarman Introduces 7 New Positions in 1st Quarter
    GuruFocus.com2 months ago

    Seth Klarman Introduces 7 New Positions in 1st Quarter

    Baupost’s new positions include companies formed by Disney-Fox merger

  • Gossamer Bio, Inc. (GOSS) Q1 2019 Earnings Call Transcript
    Motley Fool2 months ago

    Gossamer Bio, Inc. (GOSS) Q1 2019 Earnings Call Transcript

    GOSS earnings call for the period ending March 31, 2019.

  • Associated Press2 months ago

    Gossamer Bio: 1Q Earnings Snapshot

    On a per-share basis, the San Diego-based company said it had a loss of 90 cents. _____ This story was generated by Automated Insights (http://automatedinsights.com/ap) using data from Zacks Investment ...

  • Business Wire2 months ago

    Gossamer Bio Announces First Quarter 2019 Financial Results

    – Multiple trial initiations and data readouts expected in the next 12 months –

  • How Much Of Gossamer Bio, Inc. (NASDAQ:GOSS) Do Insiders Own?
    Simply Wall St.2 months ago

    How Much Of Gossamer Bio, Inc. (NASDAQ:GOSS) Do Insiders Own?

    Want to participate in a short research study? Help shape the future of investing tools and you could win a $250 gift...

  • Business Wire2 months ago

    Gossamer Bio to Announce First Quarter 2019 Financial Results and Host Conference Call and Webcast on May 14, 2019

    Gossamer Bio, Inc.  , a clinical-stage biopharmaceutical company focused on discovering, acquiring, developing and commercializing therapeutics in the disease areas of immunology, inflammation and oncology, today announced that it will report its first quarter 2019 financial results on Tuesday, May 14, 2019.

  • Business Wire3 months ago

    Gossamer Bio Secures Debt Facility for up to $150 Million

    Gossamer Bio, Inc. (GOSS), a clinical-stage biopharmaceutical company focused on discovering, acquiring, developing and commercializing therapeutics in the disease areas of immunology, inflammation and oncology, today announced it entered into a five-year senior debt facility led by MidCap Financial (MidCap). The lenders under the debt facility, including affiliates of MidCap, will make available to Gossamer an aggregate principal amount up to $150 million. The facility provides the company with access to capital for general corporate purposes and to support the development of Gossamer’s development candidates.

  • Business Wire3 months ago

    Gossamer Bio Announces Participation in Bank of America Merrill Lynch Health Care Conference 2019

    Gossamer Bio, Inc. (GOSS), a clinical-stage biopharmaceutical company focused on discovering, acquiring, developing and commercializing therapeutics in the disease areas of immunology, inflammation and oncology, today announced that Sheila Gujrathi, M.D., Chief Executive Officer and Co-Founder, will participate in a fireside chat at the Bank of America Merrill Lynch Health Care Conference on Tuesday, May 14 at 1:00 p.m. PT. Gossamer Bio is a clinical-stage biopharmaceutical company focused on discovering, acquiring, developing and commercializing therapeutics in the disease areas of immunology, inflammation and oncology.

  • Business Wire4 months ago

    Gossamer Bio Announces 2018 Annual Financial Results

    Gossamer Bio, Inc. , a clinical-stage biopharmaceutical company focused on discovering, acquiring, developing and commercializing therapeutics in the disease areas of immunology, inflammation and oncology, today announced its financial results for the year ended December 31, 2018 and provided an update on recent corporate developments.

  • Business Wire5 months ago

    Gossamer Bio Announces Participation in Upcoming Investor Conferences

    Gossamer Bio, Inc.  , a clinical-stage biopharmaceutical company focused on discovering, acquiring, developing and commercializing therapeutics in the disease areas of

  • GuruFocus.com5 months ago

    Gossamer Aims to Be Genentech Clone

    The executive chairman of Gossamer Bio (NASDAQ: GOSS) has a lofty goal for the company: Be the next version of Genentech, the biotechnology giant that is now a subsidiary of Roche (OTCPK: RHHBY). The odds are high, but Faheem Hasnain's track record suggests he may have assembled just the team to make that dream a reality. If the company comes anywhere near being the next Genentech, the share price will prove to be the biggest bargain since the purchase of Alaska.

  • Business Wire5 months ago

    Gossamer Bio Announces Closing of Initial Public Offering and Full Exercise of Underwriters’ Option to Purchase Additional Shares

    Gossamer Bio, Inc. (GOSS), a clinical-stage biopharmaceutical company focused on discovering, acquiring, developing and commercializing therapeutics in the disease areas of immunology, inflammation and oncology, today announced the closing of its previously announced initial public offering of 19,837,500 shares of its common stock, which includes the exercise in full by the underwriters of their option to purchase 2,587,500 additional shares, at a price to the public of $16.00 per share. Including the option exercise, the aggregate gross proceeds to Gossamer Bio from the offering, before deducting the underwriting discounts and commissions and other offering expenses, were $317.4 million. BofA Merrill Lynch, SVB Leerink, Barclays and Evercore ISI acted as joint book-running managers for the offering.

  • IPO Market Momentum Gains Speed, Fueled By Biotech Sector
    Investor's Business Daily5 months ago

    IPO Market Momentum Gains Speed, Fueled By Biotech Sector

    The IPO market is expected to show another uptick in volume this week as six initial public offerings are set to price and raise $882.6 million in proceeds. It follows three IPOs last week.

  • Business Wire5 months ago

    Gossamer Bio Announces Pricing of Initial Public Offering

    Gossamer Bio, Inc. (GOSS), a clinical-stage biopharmaceutical company focused on discovering, acquiring, developing and commercializing therapeutics in the disease areas of immunology, inflammation and oncology, today announced the pricing of its initial public offering of 17,250,000 shares of common stock at a public offering price of $16.00 per share. The shares are expected to begin trading on the Nasdaq Global Select Market on February 8, 2019 under the ticker symbol “GOSS.” All of the shares are being offered by Gossamer Bio. The gross proceeds from the offering, before deducting underwriting discounts and commissions and other offering expenses payable by Gossamer Bio, are expected to be $276.0 million.

  • Benzinga6 months ago

    IPO Outlook For The Week: Biotechs And Blank Checks

    For a more comprehensive IPO calendar, check out the offering in Benzinga Cloud . IPO dates below are expected but not confirmed. Alector, Inc. (ALEC) will issue 9.25 million shares between $18 and $20 ...